4th Drug Development Forum

OCTOBER 28–29, 2019 | THE COLONNADE HOTEL | BOSTON

As many blockbuster products face the loss of exclusivity, life science organizations face staunch competition from generic and biosimilar products to maintain their stronghold in certain markets. There is a lot riding on the success of new drug development, and companies are increasingly turning to external sources of innovation to supplement organic pipeline growth and replace key products within their portfolios.

 

Biotechs continue to push the boundaries of R&D innovation, exploring specialized areas of research, often entering undefined, first-in-class territory. However, changing regulatory requirements, payer expectations, and investor demands make drug development and commercialization an increasingly risky endeavor, leaving little to no margin for error. It takes strong leadership, a well-articulated and communicated shared vision, and innovative partnerships to navigate the competitive landscape and ensure the successful development of a commercially viable product in today’s healthcare environment.

 

FierceBiotech’s 4th Drug Development Forum features executive leadership perspectives from biotech and big pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend and unlock the potential of a licensing, joint venture or M&A deal.

Attendees can look forward to the following benefits

  • Interact with fellow biotech, mid-sized and large pharma company leaders and trade ideas for tackling the biggest industry challenges, from preclinical research through pivotal trials and beyond
  • Optimize early phase clinical activity to ensure successful trial execution and regulatory approval
  • Develop effective strategies for collaboration between commercial and R&D teams to allow for critical inputs in early-stage decision-making
  • Streamline insight sharing across functional lines to guide a product from discovery to launch
  • Discuss innovative deal structures and investment models that can de-risk collaborations and partnerships, and help assist the development of drugs
  • Examine key factors for the successful integration of an M&A target or licensed product/portfolio

 

Graphic 1

Help Shape the Agenda

Contact us today to get involved as a speaker or panelist
Group
Graphic 2

Join biotech leaders

Register now to benchmark & network with 200+ attendees
Group
Graphic 3

SPONSORSHIP OPPORTUNITIES

Share expertise, showcase your technologies, products & services
Group

2018 Featured Speakers

Girish Aakalu IPSEN, VP, Global Head of External Innovation
Girish Aakalu

VP, Global Head of External Innovation
IPSEN 

ROY BAYNES  Senior Vice President, Head of Clinical Development MERCK
Roy Baynes

CMO, Senior Vice President, Head of Clinical Development
MERCK

Lawrence Bloch President INFINITY PHARMACEUTICALS 
Lawrence Bloch

President
INFINITY PHARMACEUTICALS 

Ramzi Dagher
Ramzi Dagher

Vice President, Worldwide Safety and Regulatory, and Regulatory Head, Europe and International
PFIZER

Nouhad Husseini Vice President, Head of Business Development REGENERON
Nouhad Husseini

Vice President, Head of Business Development
REGENERON

Ravi Kiron Head, BioPharma External Innovation EMD SERONO 
Ravi Kiron

Head, BioPharma External Innovation
EMD SERONO 

Agustin Melian, Senior Vice President, Global Medical Sciences, ALEXION PHARMACEUTICALS
Agustin Melian

Senior Vice President, Global Medical Sciences
ALEXION PHARMACEUTICALS

Salim Mujais Senior Vice President, Global Therapeutics Head, Specialty Pharma ASTELLAS 
Salim Mujais

Senior Vice President, Global Therapeutics Head, Specialty Pharma
ASTELLAS 

Sridhar Ramaswamy Vice President, Translational R&D TESARO
Sridhar Ramaswamy

Vice President, Translational R&D
TESARO

Jeremy Sohn Vice President, Global Head of Digital Business Development & Licensing NOVARTIS
Jeremy Sohn

Vice President, Global Head of Digital Business Development & Licensing
NOVARTIS

2019 SPONSORING ORGANIZATION